Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab).
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 15523367.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Three patients with refractory pemphigus vulgaris improved after rituximab, an anti-CD20 monoclonal antibody directed against B cells. Treatment was well tolerated immediately, but one patient developed fatal pneumocystis carinii pneumonia. Serious infections have occurred in several pemphigus patients treated with rituximab and immunosuppressive medications, warranting further evaluation of risk-benefit ratio.
Medical subject headings
- Antibodies, Monoclonal
- Antigens, CD20
- Dermatologic Agents
- Pemphigus